Two of our companies on site have successfully completed a collaboration to assess small molecules identified from an initial cheminformatics drug screen in a bespoke cell-based assay developed by RxCelerate on one of PlaqueTec’s targets discovered in pilot studies.
PlaqueTec identifies endotype-specific biomarkers to advance precision medicine for coronary artery disease while RxCelerate is an international out-sourced drug discovery and development service provider.
The collaborative project was aimed at assessing the small molecules in a functional cell-based assay offered through RxCelerate’s bespoke services.
The project has enabled the lead compounds to be characterised successfully, demonstrating the value of the assay in the progress of PlaqueTec’s mission to endotype CAD and develop personalised interventions to transform patient care.
All of us here at BRC think this is a great collaboration and hope that the successful work continues!
To see the full article please click below